

# DRIVE RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE

July 2016



Remember: Clicking the **coloured links** will take you to more information!

Don't miss a beat - DRIVE-AB is on **Twitter!** Follow us at **@DRIVE\_AB**.

Please tell us your news so that we can include it in the next newsletter! Send your information to **Victoria Wells** ([vwells@bsac.org.uk](mailto:vwells@bsac.org.uk)).

**Interested in getting involved?** Just go to our website and click "Stakeholder Engagement" to find out all you need to know about getting involved with the project!

Or, fill out our **Expression of Interest Form** for stakeholders to let us know exactly how you or your organization would like to engage with the project. Please share this newsletter with other interested stakeholders as well!

## **DRIVE-AB Conference: Stimulating innovation, sustainable use and global access to antibiotics**



### **2 June 2016**

DRIVE-AB held a high-level conference to identify and evaluate reward models that are feasible, practical and can be implemented globally. It attracted more than 180 policy makers, regulatory and public health experts, economists and research and industry experts. For a **summary of the meeting and to see slide sets that were presented, please see the website**. A full post-conference report outlining the meeting outcomes and key messages from discussions will be available soon. A **detailed outline of the reward models that were discussed at the conference can be found on our website**.

**Council of the European Union recognizes work done by  
DRIVE-AB in their conclusions on the next steps for the EU**



to combat antimicrobial resistance (AMR) under a One Health approach.



**DRIVE-AB Metrics & Indicators of Responsible Antibiotic Use Included in ECDC's Draft EU Guidelines of Human Antibiotic Use**



**DRIVE-AB partners help to lead on one of the world's largest public-private partnerships focusing on antibiotic resistance, The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to provide non-equity, non-dilutive funding to preclinical companies pursuing antibacterial products.**

## Recent DRIVE-AB outputs

We have released our preliminary findings regarding some promising reward models to stimulate antibiotic innovation. [Click to read more.](#)

We have released a final report on the quality indicators and quantity metrics of responsible antibiotic use. [Click here to read.](#)

To view all DRIVE-AB outputs to date, please see our [website](#).

## What have we been up to?



DRIVE-AB distributed policy briefs at a side event of the **World Health Assembly (23-28 May)** and the launch event of the **Global Antibiotic Research and Development (GARD) Partnership (May 24)**. The consortium will also be delivering a policy brief to the **United Nations General Assembly** from 13-26 September. To date, DRIVE-AB has produced two policy briefs:

- Policy Brief: **“The necessity for greater antibiotic innovation”**
- Policy Brief: **“The role for non-profit antibiotic developers”**



The **Bio International Convention** was held in **San Francisco from 6-9 June, 2016**, and was attended by **DRIVE-AB partner Ursula Theuretzbacher**. At this meeting the IMI ND4BB programme including DRIVE-AB was presented, new economic models were discussed and feedback was provided. Four special sessions were dedicated to the resistance problem and how to stimulate antibiotic R&D.



DRIVE-AB was well represented at the 16th Biennial SMDM-European Conference in London on 12-14 June, where DRIVE-AB partner Abigail Colson gave a presentation on health technology assessment processes for antibiotics in Europe and described what DRIVE-AB hopes to achieve in the arena.



DRIVE-AB Communications co-leader, Dr Ursula Theuretzbacher, presented at a **Bio2Device Group meeting** on 14 June, 2016 on "How to stimulate and incentivize the development of new, needed antibiotics". **The slide set is available online.**



**The Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria held a public meeting in Washington, D.C. on 21-22 June, 2016, where DRIVE-AB partner Kevin Outterson gave a talk on "Economic Incentives for Antibiotics: the DRIVE-AB Approach".**



**On 27 June, 2016, DRIVE-AB was represented at the Thirteenth Meeting of WHO Patient Safety Programme and Industry Representatives, where consortium partner Chantal Morel gave a presentation on the progress of our novel economic models to drive innovation.**

If you have news that has not been included here, please send the details to **Victoria Wells** ([vwells@bsac.org.uk](mailto:vwells@bsac.org.uk)) ASAP for inclusion in the next newsletter.

## Project updates by work package

### Work Package 1

#### WP1A: Responsible use of antibiotics, new and old

In addition to releasing their **final results on qualitative and quantitative indicators and metrics for responsible antibiotic use**, the slide sets and podcasts of the team's **train-the-trainer event** in April 2016, where they presented these results, **are now online**. These indicators and metrics will now be further developed by evaluating their feasibility, their application in clinical studies, their implementation in stewardship policies and their use for education and teaching material. The team is also in the process of piloting a survey to develop a definition of "responsible antibiotic use" which will be administered to a variety of stakeholders. The team was also represented at a meeting with the European Centre for Disease Prevention and Control on 9-10 June, where they presented on 'guidelines for the prudent use of antimicrobials in human medicine'. For more information on the group's progress or to register your interest in contributing to the survey, please see WP1A's **stakeholder engagement webpage**.

#### WP1B: Setting, communicating and revising public health priorities

The team has completed the development of simulation models of transmission of antibiotic-resistant bacteria within a hospital and throughout a region, with the ability to modify variables to affect model outcomes and enhance the accuracy of predictions. They have also assembled databases from surveillance systems to estimate model parameters, validate the models and assess the impact of antibiotic resistance. The group is now working on models to predict the global spread and impact of antibiotic-resistant bacteria and will be publishing articles on the transmission of antibiotic-resistant bacteria as well as on the impact of tourism and medical tourism. For more information on the group's progress, please see WP1B's **stakeholder engagement webpage**.

### **WP1C: Antibiotic Evaluation**

The team has successfully compiled information on priority pathogens, current treatment options, resistance mechanisms, potential future resistance scenarios and possible drugs in the pipeline. The next steps for this group are to fit this information into a valuation framework, identify the data gaps and conduct expert judgement interviews. WP1C has also prepared a manuscript for the Journal of Antimicrobial Chemotherapy on “lessons learned from a pre-antibiotic era” and plan to prepare a manuscript on the “framework for valuing antibiotics”. For more information on the group’s progress, please see WP1C’s [stakeholder engagement webpage](#).

## **Work Package 2**

### **WP2: Creation and testing of new economic models**

In addition to releasing a [shortlist of antibiotic R&D incentives](#) and delivering [two policy briefs](#), the team held a very successful stakeholder meeting with high-level policy makers, regulators and experts after the [DRIVE-AB Conference](#) in June to gather feedback that they will use to further refine their incentives. The group has also completed agent-based modelling of drug pipelines in order to test the effectiveness of mechanisms designed to stimulate antibiotic development. In addition, a manuscript on “antibiotics from marketing authorization to use” has been submitted and is currently under review. Moving forward, the team will produce manuscripts on “an in-depth analysis of antibacterial SMEs”, “interventions to support sustainable use of antibiotics, lessons learnt from medical opioids” and the “future impact of alternative technologies on antibiotic markets”. The next steps for this team are to marry incentives with sustainable use and equitable availability policies, develop governing and financing mechanisms, pursue pilots of incentive policies and develop an implementation plan. For more information on the group’s progress, please see WP2’s [stakeholder engagement webpage](#).

## **Work Package 3**

### **WP3A: Project management and governance**

Along with ongoing project monitoring and management activities, the team has been busy organising the third DRIVE-AB General Assembly which will take place in October, as well as holding monthly scientific forums for DRIVE-AB participants. The group has also had a midterm project review meeting with the Innovative Medicines Initiative, where the project was evaluated by external experts. The feedback received from this meeting will inform future work and activities. For more information on the group’s progress, please see WP3A’s [webpage](#).

### **WP3B: Stakeholder platform and external communication**

In addition to the organization and delivery of the [DRIVE-AB Conference, “Stimulating sustainable use and global access to antibiotics”](#), the team has also released a [summary of the event](#) and is busy working on a full post-conference report, which will be available soon. The group is also planning a strategy meeting to evaluate and update the project communications strategy in response to the rapidly changing landscape of the antibiotic resistance field. The new strategy will help to inform and optimize communications and stakeholder activities in the final year of the project. The group also continues to manage project communications both internally and externally by monitoring and updating the website and social media and managing potential and novel stakeholders. For more information on the group’s progress, please see WP3B’s [webpage](#).

## **Remember...**

Should you wish to receive more detailed information, nominate another stakeholder or update us on your activities relevant to the project, please contact [Victoria Wells](#), DRIVE-AB Communications Officer.

